logo

Last Update

This profile was last updated on 8/11/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Pamela Hay?

Pamela A. Hay

Senior Vice President of Corporate Development

Dyax Corp.

HQ Phone:  (617) 225-2500

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Dyax Corp.

55 Network Drive

Burlington, Massachusetts,01803

United States

Company Description

Dyax is a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. Dyax is developing DX-2930, a fully human monoclonal antibody, for the prevention of HAE attacks. Additionally, Dyax markets ...more

Background Information

Employment History

Senior Legal Positions

Biogen Idec Inc.


Co-Founder and President

Visgo


Partner

Red Sky Partners, LLC.


Chief Commercial Officer

Domantis Limited


Affiliations

NeuroHealing Pharmaceuticals Inc

Advisor


Education

B.A.

Biology

Cornell University


J.D.

Biology

University of Wisconsin Law School


Ms Hay

Dyax Corp.


Ms Hay

T Cell Sciences and Corporate Counsel


Web References(27 Total References)


Team - NeuroHealing Pharmaceuticals Inc.

www.neurohealing.com [cached]

Pamela Hay, J.D.
Pamela Hay is a business development and operations consultant for early stage biotechnology companies. She was Chief Commercial Officer at Domantis Ltd from 2001 until its acquisition by GSK in 2007, where she oversaw commercial development, including completion of major alliances with Abbott and BMS and additional deal negotiations that concluded the company purchase. Previously, she was SVP, Corporate Development at Dyax Corp where she was responsible for the negotiation of more than 60 licenses and collaborations as well as the legal and IP functions. She has also held senior legal positions at T Cell Sciences and Biogen. Pamela has a JD from the University of Wisconsin and a BA in Biology from Cornell University.


NeuroHealing Pharmaceuticals Inc.

www.neurohealing.com [cached]

Pamela Hay, J.D.
Pamela Hay, J.D. Pamela Hay is a business development and operations consultant for early stage biotechnology companies. She was Chief Commercial Officer at Domantis Ltd from 2001 until its acquisition by GSK in 2007, where she oversaw commercial development, including completion of major alliances with Abbott and BMS and additional deal negotiations that concluded the companys purchase. Previously, she was SVP, Corporate Development at Dyax Corp where she was responsible for the negotiation of more than 60 licenses and collaborations as well as the legal and IP functions. She has also held senior legal positions at T Cell Sciences and Biogen. Pamela has a JD from the University of Wisconsin and a BA in Biology from Cornell University.


News & Headlines: Diversys Names Pamela Hay Chief Commercial Officer

www.otohns.net [cached]

2001 NOV 12 - (NewsRx.com & NewsRx.net) -- Diversys Ltd., a protein engineering company, has hired business development executive Pamela Hay as chief commercial officer.
Ms. Hay is considered an expert in the developing business opportunities in the fields of protein repertoires and protein engineering, and is a prolific negotiator of deals in this sector, according to the company. Ms. Hay has more than 15 years of legal and business development experience with major biotechnology and pharmaceutical companies. With a degree in biology from Cornell and a law degree from the University of Wisconsin. She joined Dyax Corp. in 1996, where she rose to become senior vice president of corporate development and strategic opportunities. Within Dyax, Ms. Hay and her team negotiated over 75 collaboration, technology transfer and license agreements involving the company's phage display technology and product leads, managed the company's growing patent portfolio and legal needs, and helped lead the acquisition of new technologies. Ms. Hay will assume responsibility for the commercialization of Diversys' protein repertoire and engineering technologies for therapeutic, diagnostic and research use. In addition, she will be in charge of business development activities and management of Diversys intellectual property portfolio. Ms. Hay will be based in Diversys' new commercial office in Cambridge, Massachusetts. This article was prepared by Health & Medicine Week editors from staff and other reports.


NeuroHealing Pharmaceuticals Inc.

www.NHpharma.com [cached]

Pamela Hay, J.D.
Pamela Hay, J.D. Pamela Hay is a business development and operations consultant for early stage biotechnology companies. She was Chief Commercial Officer at Domantis Ltd from 2001 until its acquisition by GSK in 2007, where she oversaw commercial development, including completion of major alliances with Abbott and BMS and additional deal negotiations that concluded the company's purchase. Previously, she was SVP, Corporate Development at Dyax Corp where she was responsible for the negotiation of more than 60 licenses and collaborations as well as the legal and IP functions. She has also held senior legal positions at T Cell Sciences and Biogen. Pamela has a JD from the University of Wisconsin and a BA in Biology from Cornell University.


Pamela Hay | Red Sky Partners

redskyco.com [cached]

Pamela Hay
Pamela Hay Partner Pamela Hay Pamela Hay Pamela Hay provides interim management and advisory services to biotech companies that are seeking to complete significant partnering or financing transactions. She has taken on acting CEO or CBO roles and served as a senior business advisor to management and investors during transition and growth phases. In these roles, she often leads the planning and negotiation of strategic transactions. She is a founding partner of Red Sky with 30 years of executive or advisory roles at more than 20 biotech companies spanning the start-up through Phase 2 product development stages in multiple therapeutic indications. Her recent Red Sky assignments have included serving as co-CEO of Harbour Antibodies where she led its sale to Harbour Biomed, lead business negotiator for Luc Therapeutics in its Novartis CNS deal and interim CBO for Nimbus Therapeutics. In addition to her role at Red Sky, Pamela is co-founder and President of Visgo Therapeutics, a start-up company developing products to treat joint diseases. Previously, Pamela was Chief Commercial Officer of Domantis Ltd, a Cambridge UK biotech company, sold to GSK for $450m in 2007 and was SVP, Corporate Development at Dyax Corp, where she designed and implemented the company's broad-based licensing and partnering programs for phage display IP and technology. Her earlier positions include General Counsel of T Cell Sciences and Corporate Attorney at Biogen. Pamela has a BA in Biology from Cornell University's School of Arts and Sciences, and a JD from the University of Wisconsin School of Law. Pamela Hay Pamela Hay Partner


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory